Cybin (HELP) Other Non-Current Liabilities (2021 - 2025)
Cybin's (HELP) quarterly Other Non-Current Liabilities came in at $19.2 million in Q3 2025, down 5.11% YoY from $20.2 million in Q3 2024, and little changed on a QoQ basis from $19.2 million in Q2 2025.
Cybin (HELP) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Cybin (HELP) has 5 years of Other Non-Current Liabilities data on file, last reported at $19.2 million in Q3 2025.
- Quarterly Other Non-Current Liabilities fell 5.11% year-over-year to $19.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $19.2 million (down 5.11% YoY) and the FY2024 annual result came in at $19.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities steadied at $19.2 million in Q3 2025, from $19.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $23.6 million in Q4 2023 to a low of $8.0 million in Q4 2022.
- A 5-year average of $14.1 million and a median of $10.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 194.72% — and 2024, when it dropped 16.33%.
- Tracing HELP's Other Non-Current Liabilities over 5 years: stood at $9.2 million in 2021, then declined by 13.0% to $8.0 million in 2022, then surged by 194.72% to $23.6 million in 2023, then dropped by 16.33% to $19.8 million in 2024, then slipped by 2.83% to $19.2 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $19.2 million (Q3 2025), $19.2 million (Q2 2025), and $19.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 19.19 Mn |
| Jun 30, 2025 | 19.19 Mn |
| Dec 31, 2024 | 19.75 Mn |
| Sep 30, 2024 | 20.23 Mn |
| Jun 30, 2024 | 18.75 Mn |
| Mar 31, 2024 | 19.03 Mn |
| Dec 31, 2023 | 23.61 Mn |
| Sep 30, 2023 | 10.68 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Dec 31, 2022 | 8.01 Mn |
| Sep 30, 2022 | 8.64 Mn |
| Dec 31, 2021 | 9.21 Mn |
| Sep 30, 2021 | 9.29 Mn |
| Jun 30, 2021 | 9.13 Mn |
| Mar 31, 2021 | 8.82 Mn |